Day: May 25, 2023

Frontline plc.’s preliminary first quarter 2023 results will be released on Wednesday May 31, 2023, and a webcast and conference call will be held at 3:00 p.m. CET (9:00 a.m. U.S. Eastern Time). The results presentation will be available for download from the Investor Relations section at www.frontlineplc.cy ahead of the conference call.  In order to attend the conference call you may do one of the following: a. WebcastGo to the Investor Relations section at www.frontlineplc.cy and follow the “Webcast” link, or access directly from the link below. Frontline plc Q1 2023 Webcast b. Conference Call Participants will need to register online prior to the conference call via the link below. Dial-in details will be available when registered.               Frontline plc Q1 2023 Conference Call A Q&A session will be held after the teleconference/webcast....

To NASDAQ Copenhagen A/S   Executive Board Lersø Parkalle 100 DK-2100 København Ø www.rd.dk Telephone +45 7012 5300 25 May 2023Company announcement number 42/2023 Result of auction of mortgage covered bonds (SDRO’s) in series 11F, 12E, 12F and 12GToday, Realkredit Danmark has completed the auctions of mortgage covered bonds (SDRO’s) in series 11F, 12E, 12F and 12G for the refinancing of FlexKort®, RD Cibor6® Green, RD Cibor6® and RD Euribor3® as of 1 July 2023. The result of the auctions is set out in the appendix to this announcement.   The Executive Board Any additional questions should be addressed to Christian Rosenstand, Head of RD Funding, phone +45 45 13 20 19.AttachmentsNr. 42_Resultat af auktioner over obligationer_ukBilag til selskabsmeddelelse nr. 42-2023_uk

SHANGHAI, China, May 25, 2023 (GLOBE NEWSWIRE) — NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the premium smart electric vehicle market, today published a notice to announce that it will hold an annual general meeting (the “AGM”) of shareholders (the “Notice of AGM”) at 10:30 am, Beijing time, on June 26, 2023 at Building 19, No. 889, Tianlin Road, Minhang District, Shanghai, People’s Republic of China, for the purposes of considering and, if thought fit, passing the proposed resolutions set forth in the Notice of AGM (the “Proposed Resolutions”). The Notice of AGM and form of proxy for the AGM are available on the Company’s website at https://ir.nio.com/generalmeeting. The board of directors of NIO fully supports the Proposed Resolutions and recommends that shareholders...

DAYTONA BEACH, Fla., May 25, 2023 (GLOBE NEWSWIRE) — Brown & Brown, Inc. (NYSE:BRO) (the “Company”) has announced the appointment of Pattysue Rauh as chief audit officer for Brown & Brown, effective July 2023. Rauh will also serve on the senior leadership team. In this new role, Rauh will lead the Company’s internal audit and compliance operations, overseeing internal controls. She will transition from her current role as executive vice president of national employee benefits within Brown & Brown’s Retail segment over the coming month. Andy Watts, chief financial officer, said, “Pattysue has been a valuable part of the Brown & Brown team for more than 25 years. She has served in various roles, including marketing, production, office leadership, and most recently, as part of the leadership team driving the continued...

– Richard Beckman, M.D., chief medical officer, transitions to senior medical advisor – – Star Seyedkazemi, Pharm.D., chief development officer, expands her responsibilities to lead Adverum’s clinical development, medical affairs and pharmacovigilance teams – REDWOOD CITY, Calif., May 25, 2023 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced new executive leadership roles that support the ongoing development of the investigational gene therapy ixoberogene soroparvovec (Ixo-vec). Ixo-vec is currently being evaluated in the Phase 2 LUNA trial as a one-time intravitreal (IVT) injection for patients in the treatment of neovascular or wet age-related macular...